Potential 20-Week Faricimab Dosing in Wet Age-Related Macular Degeneration

20260 citationsJournal Articlehybrid Open Access

Authors

Aude Ambresin · SIB Swiss Institute of Bioinformatics

Varun Chaudhary · McMaster University

Richard Gale · York Teaching Hospital NHS Foundation Trust

Adrian Koh · Eye & Retina Surgeons

Nikolas London · California Retina Consultants

PJ Patel · Moorfields Eye Hospital NHS Foundation Trust

Anna C.S. Tan

Abstract

Patients with nAMD in TENAYA/LUCERNE always on extended faricimab dosing (≥12-weeks) achieved robust disease control throughout 2 years. Additionally, 56% of patients could have potentially extended to every-20-week dosing had the protocol allowed.

Topics & Keywords

Retinal Diseases and Treatments Ophthalmology and Visual Impairment Studies Ocular Diseases and Behçet’s Syndrome

Publication Details

Published in: Ophthalmology Retina

DOI: 10.1016/j.oret.2026.02.001

Field-Weighted Citation Impact: 0.00

Command Palette

Potential 20-Week Faricimab Dosing in Wet Age-Related Macular Degeneration

Authors

Abstract

Topics & Keywords

Publication Details